Recursion Pharmaceuticals prices $200M stock offering

Recursion Pharmaceuticals (RXRX) priced a $200M stock offering at $3.25 per share, with gross proceeds before expenses. The offering, managed by UBS, Leerink, and others, includes participation from institutional investors. The company focuses on AI-driven drug discovery and development.

Original reporting
Published Oct 15, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RXRX
Bearish
high confidence
Mentioned
$RXRX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RXRXBearishHigh
01

Why it matters

The $200M raise provides cash for R&D and operational expansion but increases share count, creating short‑term dilution risk.

02

Market read

Primary disclosure of a sizable equity raise; traders can act on expected short‑term price pressure.

03

What to watch

Potential strategic investors participating in the offering could provide validation and future partnership opportunities.

Relevance 8/10Novelty 8/10Timing: today

Background

Recursion is a clinical‑stage AI‑enabled drug discovery firm that has been expanding its pipeline across multiple therapeutic areas.

Company-level read

Ticker impact

$RXRXBearishHigh confidence
Context

Recursion Pharmaceuticals announced pricing of a $200M public stock offering of 61.5M shares at $3.25 each.

Expected impact

likely downside as the market prices in dilution from the $200M raise

Evidence & confidence

A sizable primary offering at a modest price signals capital need and adds supply, which historically depresses price in the near term.

Market effects

Adds to recent fundraising activity in the AI‑driven biotech sector, may prompt peers to consider similar capital structures.

Limited to U.S. biotech investors; no broader regional effect.

Modest, as the raise is company‑specific and does not alter macro trends.

Counterpoint

If the capital is deployed efficiently into high‑margin AI drug pipelines, the dilution could be offset by future revenue growth.

Key entities

  • Recursion Pharmaceuticals Inc.

    Clinical‑stage AI drug discovery company issuing new shares.

  • Goldman Sachs & Co. LLC

    Joint bookrunning manager for the offering.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.